将基于纳米载体的药物传递纳入使用，可以有效克服常规化疗的局限性，提供了一个有前景的替代方案。多柔比星（DOXO）是一种广泛用于乳腺癌治疗的有效化疗药物。球状蛋白牛血清白蛋白（BSA）在药物应用中具有潜在的载体作用。本研究旨在通过脱溶法制备DOXO偶联的糖化BSA纳米颗粒，以提高其对过度表达在乳腺癌细胞上的GLUT5转运体的靶向能力。使用果糖胺测定法和傅里叶变换红外光谱法分别确定纳米颗粒表面果糖胺结构的含量和结构变化。此外，利用电子显微镜和动态光散射技术进一步表征合成的BSA纳米颗粒。结果显示，DOXO偶联的糖化BSA纳米颗粒呈球形，其流体动力直径约为60.74 nm，ζ-电位约为- 42.20 mV。此外，对经合成的DOXO偶联的糖化BSA纳米颗粒进行了不同条件下的DOXO释放行为研究。最后，发现DOXO偶联的糖化BSA纳米颗粒对MCF-7和MDA-MB-231细胞均具有细胞毒性。我们的研究结果明确表明，药物偶联的糖化BSA纳米颗粒是用于乳腺癌治疗的靶向药物传递平台的潜在候选物。 © 2023 Elsevier B.V. 保留所有权利。

Incorporation of the nano-based carriers into drug delivery provides a promising alternative to overcome the limitations of the conventional chemotherapy. Doxorubicin (DOXO) is an effective chemotherapeutic drug widely used in chemotherapy for breast cancer treatment. A globular protein bovine serum albumin (BSA) holds great potential as carriers in pharmaceutical applications. This work is aimed at developing the DOXO-coupled glycated BSA nanoparticles via desolvation method for improving the capability of targeting the GLUT5 transporters over-expressed on breast cancer cells. Fructosamine assay and Fourier transform infrared spectroscopy were employed to determine the content of fructosamine structure and structural changes on the surfaces of nanoparticles, respectively. Additionally, the synthesized BSA nanoparticles were further characterized by electron microscopy and dynamic light scattering. Results revealed that the DOXO-coupled glycated BSA nanoparticles were spherically shaped with a hydrodynamic diameter of ~60.74 nm and a ζ-potential of ~ - 42.20 mV. Moreover, the DOXO release behavior of as-synthesized DOXO-coupled glycated BSA nanoparticles was examined under different conditions. Finally, the DOXO-coupled glycated BSA nanoparticles were found to exhibit cytotoxicity toward both MCF-7 and MDA-MB-231 cells. Our findings evidently suggested that the drug-coupled glycated BSA nanoparticles serve as the potential candidates for targeted drug delivery platform used in breast cancer therapy.Copyright © 2023 Elsevier B.V. All rights reserved.